Looks like women in the US have to wait a little longer for another option to deal with hot flashes.
Astellas Pharma has announced that the US Food and Drug Administration is extending the original priority review Prescription Drug User Fee Act goal date for fezolinetant, its promising new investigational non-hormonal therapy for hot flashes.
According …
Keep reading with a 7-day free trial
Subscribe to Hotflash Inc to keep reading this post and get 7 days of free access to the full post archives.